GlobeNewswire

SolarWinds Introduces Cloud-First Backup Service for Physical and Virtual Servers

Dela

SolarWinds Backup designed to reduce cost and complexity of data protection
Solution features proven technology already used by MSPs to protect thousands of customers worldwide

AUSTIN, Texas, March 27, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today marked World Backup Day a few days early by introducing its first backup solution targeted for direct use by end-user customers. SolarWinds Backup is a cloud-first backup service developed to protect virtual and physical servers. It is built upon the company's own proven technology already used by Managed Services Providers (MSPs) to securely and efficiently protect the data assets of thousands of organizations worldwide. The product has been designed from the ground up to reduce cost and complexity without sacrificing speed or reliability.

With many backup alternatives to choose from in a competitive marketplace, almost half of IT professionals are marginally satisfied or dissatisfied with their current backup products, according to findings from a recent survey of SolarWinds' 145,000-member THWACK user community. Almost 10 percent of respondents admitted to being dissatisfied and actively looking to switch products. Forty-two percent cited cost, and 31 percent chose complexity as their most significant pain points.

With many customers open to considering new alternatives, SolarWinds developed an easy-to-use and highly affordable cloud backup service that more fully addresses users' biggest challenges. SolarWinds Backup can reduce administrative time spent managing backups and eliminate local backup storage requirements. The web-based console offers at-a-glance monitoring of backup status, and enables recovery from anywhere - even using mobile devices.  Backups typically can begin running in minutes, with no need to provision storage or manually configure cloud connections.  

"Customers told us loud and clear that backups today are just too time-consuming and expensive to manage," said Christoph Pfister, executive vice president and head of products, SolarWinds. "Through our MSP business, we already help many IT professionals overcome these challenges. Now, we're committed to extending these benefits deeper into our customer base, bringing our industry-renowned simplicity, power, and affordability to the backup and recovery solutions market."

"SolarWinds Backup is easy to use and delivers consistently successful backups," said Neil Jones, system administrator at CFO Network, an accounting, analysis, and consulting firm based in North Little Rock, Arkansas. "We previously used an older enterprise backup product, but the backups weren't reliable.  We also used an inexpensive file-level backup product that restored so slowly it would take weeks if we ever had to do a full recovery. SolarWinds Backup has been a great alternative because it's fast and reliable. The web-based interface is very intuitive. Green means our backups are good to go, and the backup profiles make it easy to customize protection for different types of servers and applications."

Simple, Fast, and Reliable Backups

SolarWinds Backup raises the bar on simplicity, while bringing the functionality and high reliability necessary to address all customer needs in an efficient cloud-first backup solution. Built-in deduplication and compression features are optimized to minimize network bandwidth requirements and speed up restores from the cloud. Local restores also can be completed using the Local SpeedVault feature.  Further, the solution allows customers to protect physical and virtual servers using a single product, thereby reducing complexity.

SolarWinds Backup also delivers the speed required to handle even large machines and databases with extremely short backup windows. Built-in compression and SolarWinds' highly efficient True Delta(TM) data deduplication technology can shrink backup windows from hours to minutes. For example, an 8TB file server with more than 1.2 million files can complete daily offsite backups in as little as four minutes. 

Finally, backups are stored in a global, purpose-built private cloud that is designed to be highly secure.  Data is encrypted in transit and at rest via AES-256 encryption, and users hold the key. A network of multiple data centers around the world helps meet data governance and privacy requirements.

Pricing and Availability

SolarWinds Backup is available immediately, with annual subscription pricing starting at $2,995*, which includes the backup software and storage space in the SolarWinds private cloud.

For more information, including a free 30-day trial of SolarWinds Backup, visit the SolarWinds website , or call +1.385.374.7024. Watch an overview video of SolarWinds Backup here.

*Prices as of March 27, 2018 in US Dollars. Pricing may vary based upon the jurisdiction and applicable currency. Please contact a local SolarWinds sales representative to find pricing specific to your jurisdiction.

Additional Resources

Connect with SolarWinds

About SolarWinds 
SolarWinds provides powerful and affordable IT management software to customers worldwide from Fortune 500® enterprises to small businesses, government agencies and educational institutions. We are committed to focusing exclusively on IT Pros, and strive to eliminate the complexity that they have been forced to accept from traditional enterprise software vendors. Regardless of where the IT asset or user sits, SolarWinds delivers products that are easy to find, buy, use, maintain, and scale while providing the power to address all key areas of the infrastructure from on premises to the Cloud. Our solutions are rooted in our deep connection to our user base, which interacts in our THWACK online community to solve problems, share technology and best practices, and directly participate in our product development process. Learn more today at www.solarwinds.com .

The SolarWinds, SolarWinds & Design, Orion, and THWACK trademarks  are the exclusive property of SolarWinds Worldwide, LLC or its affiliates, are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other SolarWinds trademarks, service marks, and logos may be common law marks or are registered or pending registration. All other trademarks mentioned herein are used for identification purposes only and are trademarks of (and may be registered trademarks) of their respective companies.

© 2018 SolarWinds Worldwide, LLC.  All rights reserved.

MEDIA CONTACTS:
Nicole Fachet
Text100
Phone: 212.871.3950
NicoleF@text100.com

Mark Stanton
SolarWinds
Phone: 512.682.9692
pr@solarwinds.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SolarWinds Worldwide, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum